Vikram Purohit
Stock Analyst at Morgan Stanley
(0.83)
# 3,593
Out of 4,818 analysts
173
Total ratings
26.98%
Success rate
-15.01%
Average return
Main Sectors:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals | Maintains: Equal-Weight | $10 → $8 | $5.58 | +43.37% | 2 | Apr 10, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $69 → $65 | $58.02 | +12.04% | 24 | Mar 24, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $104.33 | +82.11% | 19 | Feb 27, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $40 → $35 | $9.96 | +251.41% | 2 | Dec 11, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.68 | +92.31% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $20.13 | +54.00% | 2 | Sep 11, 2024 | |
| SLRN Acelyrin | Maintains: Equal-Weight | $13 → $6 | $2.30 | +161.44% | 7 | Aug 19, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $59 → $64 | $58.43 | +9.53% | 6 | Aug 7, 2024 | |
| ABSI Absci | Initiates: Overweight | $7 | $3.21 | +118.41% | 1 | Jul 3, 2024 | |
| ASND Ascendis Pharma | Maintains: Equal-Weight | $116 → $140 | $158.46 | -11.65% | 18 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $16 | $6.84 | +133.92% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $3.98 | +653.77% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $22 | $7.64 | +188.15% | 6 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $14.45 | -30.80% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $1.15 | +421.74% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $8.90 | +371.91% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $23 | $0.78 | +2,784.62% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $30.89 | +32.73% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $20.41 | +95.98% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $0.91 | +1,328.41% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $25.46 | +49.25% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $14.27 | +40.15% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $9.44 | +5.93% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $18 → $7 | $28.90 | -75.78% | 8 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.63 | +1,249.69% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $9.24 | +116.45% | 2 | Aug 5, 2020 |
Recursion Pharmaceuticals
Apr 10, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $5.58
Upside: +43.37%
Incyte
Mar 24, 2025
Maintains: Equal-Weight
Price Target: $69 → $65
Current: $58.02
Upside: +12.04%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $104.33
Upside: +82.11%
Zenas BioPharma
Dec 11, 2024
Maintains: Overweight
Price Target: $40 → $35
Current: $9.96
Upside: +251.41%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.68
Upside: +92.31%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $20.13
Upside: +54.00%
Acelyrin
Aug 19, 2024
Maintains: Equal-Weight
Price Target: $13 → $6
Current: $2.30
Upside: +161.44%
Halozyme Therapeutics
Aug 7, 2024
Maintains: Overweight
Price Target: $59 → $64
Current: $58.43
Upside: +9.53%
Absci
Jul 3, 2024
Initiates: Overweight
Price Target: $7
Current: $3.21
Upside: +118.41%
Ascendis Pharma
May 16, 2024
Maintains: Equal-Weight
Price Target: $116 → $140
Current: $158.46
Upside: -11.65%
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $6.84
Upside: +133.92%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $3.98
Upside: +653.77%
Feb 28, 2024
Maintains: Equal-Weight
Price Target: $20 → $22
Current: $7.64
Upside: +188.15%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $14.45
Upside: -30.80%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $1.15
Upside: +421.74%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $8.90
Upside: +371.91%
Jun 5, 2023
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $0.78
Upside: +2,784.62%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $30.89
Upside: +32.73%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $20.41
Upside: +95.98%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $0.91
Upside: +1,328.41%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $25.46
Upside: +49.25%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $14.27
Upside: +40.15%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $9.44
Upside: +5.93%
Dec 10, 2021
Downgrades: Underweight
Price Target: $18 → $7
Current: $28.90
Upside: -75.78%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.63
Upside: +1,249.69%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $9.24
Upside: +116.45%